About Auxilium Pharmaceuticals (NASDAQ:AUXL)
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men's healthcare. The company's products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-76.75%
Return on Assets-11.59%
Auxilium Pharmaceuticals (NASDAQ:AUXL) Frequently Asked Questions
What is Auxilium Pharmaceuticals' stock symbol?
Auxilium Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUXL."
How were Auxilium Pharmaceuticals' earnings last quarter?
Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) released its quarterly earnings data on Thursday, October, 30th. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.30. The biopharmaceutical company had revenue of $109.60 million for the quarter, compared to the consensus estimate of $101.02 million. Auxilium Pharmaceuticals had a negative net margin of 29.78% and a negative return on equity of 76.75%. The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.17 earnings per share. View Auxilium Pharmaceuticals' Earnings History.
Who are some of Auxilium Pharmaceuticals' key competitors?
Some companies that are related to Auxilium Pharmaceuticals include Etsy (ETSY), Senior Housing Properties Trust (SNH), UMB Financial (UMBF), Firstmerit (FMER), Starz Acquisition (STRZA), Ligand Pharmaceuticals (LGND), First Niagara Financial Group (FNFG), FireEye (FEYE), Neogen (NEOG), Advanced Accelerator Application (AAAP), Selective Insurance (SIGI), United Bankshares (UBSI), Beacon Roofing Supply (BECN), DreamWorks Animation (DWA), MB Financial (MBFI), Navient (NAVI), Sapient (SAPE) and Red Rock Resorts (RRR).
Has Auxilium Pharmaceuticals been receiving favorable news coverage?
Media coverage about AUXL stock has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Auxilium Pharmaceuticals earned a daily sentiment score of 0.16 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.44 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Auxilium Pharmaceuticals?
Shares of AUXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auxilium Pharmaceuticals' stock price today?
One share of AUXL stock can currently be purchased for approximately $36.47.
How big of a company is Auxilium Pharmaceuticals?
Auxilium Pharmaceuticals has a market capitalization of $1.85 billion.
How can I contact Auxilium Pharmaceuticals?
Auxilium Pharmaceuticals' mailing address is 640 Lee Rd, CHESTERBROOK, PA 19087-5636, United States. The biopharmaceutical company can be reached via phone at +1-484-3215900.
MarketBeat Community Rating for Auxilium Pharmaceuticals (AUXL)MarketBeat's community ratings are surveys of what our community members think about Auxilium Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Auxilium Pharmaceuticals (NASDAQ:AUXL) Analyst Ratings History
(Data available from 4/21/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Auxilium Pharmaceuticals (NASDAQ:AUXL) Earnings History and Estimates Chart
Auxilium Pharmaceuticals (NASDAQ AUXL) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/30/2014||Q314||($0.03)||$0.27||$101.02 million||$109.60 million||View||N/A|
|8/7/2014||Q214||($0.21)||($0.54)||$482.80 million||$83.00 million||View||Listen|
|5/5/2014||Q114||($0.14)||($0.39)||$89.20 million||$8.50 million||View||Listen|
|2/28/2014||Q413||$0.22||$0.27||$111.83 million||$125.90 million||View||Listen|
|11/6/2013||Q3 2013||$0.05||$0.10||$102.49 million||$108.10 million||View||N/A|
|8/1/2013||Q2 2013||($0.03)||$0.02||$91.43 million||$100.50 million||View||Listen|
|4/29/2013||Q1 2013||$0.02||($0.05)||$81.23 million||$66.20 million||View||Listen|
|2/26/2013||Q4 2012||$1.72||$1.83||$171.20 million||$172.50 million||View||Listen|
|11/7/2012||Q312||($0.07)||($0.21)||$79.54 million||$71.00 million||View||N/A|
Auxilium Pharmaceuticals (NASDAQ:AUXL) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Auxilium Pharmaceuticals (NASDAQ AUXL) Insider Trading and Institutional Ownership History
Auxilium Pharmaceuticals (NASDAQ AUXL) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/5/2014||Adrian Adams||CEO||Sell||40,000||$33.97||$1,358,800.00|| |
|12/5/2014||Paul A Friedman||Director||Sell||29,689||$33.73||$1,001,409.97|| |
|12/3/2014||Oliver Fetzer||Director||Sell||100,000||$34.02||$3,402,000.00|| |
|11/25/2014||James Patrick Tursi||Insider||Sell||13,713||$34.12||$467,887.56|| |
|11/21/2014||Andrew I Koven||CAO||Sell||139,683||$33.43||$4,669,602.69|| |
|11/21/2014||James Patrick Tursi||Insider||Sell||74,648||$33.19||$2,477,567.12|| |
|11/21/2014||Jennifer Lou Armstrong||SVP||Sell||75,803||$33.50||$2,539,400.50|| |
|3/14/2014||Tito Benjamin Del, Jr.||EVP||Sell||32,032||$29.50||$944,944.00||22,735|| |
|3/5/2014||Rolf Classon||Director||Sell||10,000||$31.85||$318,500.00||22,937|| |
|12/13/2013||Tito Benjamin Del, Jr.||EVP||Sell||4,602||$20.50||$94,341.00||13,710|| |
|12/11/2013||James Fickenscher||CFO||Sell||71,067||$20.37||$1,447,634.79||45,132|| |
|8/15/2013||Oliver Fetzer||Director||Sell||1,900||$18.75||$35,625.00||14,197|| |
|5/20/2013||William Mckee||Director||Sell||2,000||$15.10||$30,200.00|| |
Auxilium Pharmaceuticals (NASDAQ AUXL) News Headlines
|Reviewing Baxalta (BXLT) & Auxilium Pharmaceuticals (AUXL)|
www.americanbankingnews.com - March 22 at 12:25 PM
|Head-To-Head Review: Auxilium Pharmaceuticals (AUXL) versus VIVUS (VVUS)|
www.americanbankingnews.com - February 14 at 3:18 AM
|Contrasting Auxilium Pharmaceuticals (AUXL) & Mediwound (MDWD)|
www.americanbankingnews.com - February 6 at 1:28 PM
|Head-To-Head Contrast: Alexion Pharmaceuticals (ALXN) vs. Auxilium Pharmaceuticals (AUXL)|
www.americanbankingnews.com - January 11 at 9:32 AM
|Cesca Therapeutics (KOOL) and Auxilium Pharmaceuticals (AUXL) Head to Head Contrast|
www.americanbankingnews.com - January 4 at 11:08 PM
|Reviewing Auxilium Pharmaceuticals (AUXL) & The Competition|
www.americanbankingnews.com - December 17 at 9:28 PM
|Contrasting Auxilium Pharmaceuticals (AUXL) and Its Competitors|
www.americanbankingnews.com - December 17 at 8:28 AM
|Analyzing Auxilium Pharmaceuticals (AUXL) and Its Competitors|
www.americanbankingnews.com - December 11 at 3:34 PM
|Auxilium Pharmaceuticals (AUXL) versus Its Peers Head-To-Head Survey|
www.americanbankingnews.com - December 10 at 7:20 PM
|Comparing Auxilium Pharmaceuticals (AUXL) and Its Peers|
www.americanbankingnews.com - December 8 at 8:40 AM
|Comparing Auxilium Pharmaceuticals (AUXL) and Its Competitors|
www.americanbankingnews.com - December 4 at 5:12 AM
|Reviewing Auxilium Pharmaceuticals (AUXL) & Its Competitors|
www.americanbankingnews.com - December 3 at 9:48 PM
|Analyzing Auxilium Pharmaceuticals (AUXL) & Its Peers|
www.americanbankingnews.com - November 26 at 9:18 PM
|Critical Analysis: Auxilium Pharmaceuticals (AUXL) versus The Competition|
www.americanbankingnews.com - November 25 at 1:22 AM
|Auxilium Pharmaceuticals (AUXL) versus Its Peers Critical Contrast|
www.americanbankingnews.com - November 19 at 11:30 AM
|Critical Analysis: Auxilium Pharmaceuticals (AUXL) vs. Peregrine Pharmaceuticals (PPHM)|
www.americanbankingnews.com - November 10 at 7:32 PM
|Auxilium Pharmaceuticals (AUXL) versus KalVista Pharmaceuticals (KALV) Head to Head Survey|
www.americanbankingnews.com - October 23 at 4:32 AM
|Fortress Biotech (FBIO) & Auxilium Pharmaceuticals (AUXL) Critical Comparison|
www.americanbankingnews.com - October 20 at 8:32 AM
|Auxilium Pharmaceuticals (AUXL) & Onconova Therapeutics (ONTX) Critical Comparison|
www.americanbankingnews.com - October 15 at 4:08 PM
|Head-To-Head Review: Auxilium Pharmaceuticals (AUXL) versus BioMarin Pharmaceutical (BMRN)|
www.americanbankingnews.com - September 28 at 10:48 AM
|Financial Survey: Auxilium Pharmaceuticals (AUXL) versus Alimera Sciences (ALIM)|
www.americanbankingnews.com - September 7 at 8:28 PM
|Auxilium Pharmaceuticals (NASDAQ:AUXL) vs. Biogen (BIIB) Head to Head Analysis|
www.americanbankingnews.com - July 24 at 8:22 PM
|Endo International (ENDP) Earnings Report: Q1 2015 Conference Call Transcript|
www.thestreet.com - May 11 at 2:46 PM
|AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements a|
biz.yahoo.com - January 30 at 4:56 PM
|AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materia|
biz.yahoo.com - January 29 at 4:50 PM
|AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD D|
biz.yahoo.com - January 27 at 1:38 PM
|AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events|
biz.yahoo.com - January 21 at 6:01 AM
|AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - December 22 at 11:16 AM
|AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - December 19 at 1:12 PM
|Why Endo Wants to Acquire Auxilium So Much|
247wallst.com - September 17 at 10:05 AM
Auxilium Pharmaceuticals (NASDAQ:AUXL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Auxilium Pharmaceuticals (NASDAQ:AUXL) Income Statement, Balance Sheet and Cash Flow Statement
Auxilium Pharmaceuticals (NASDAQ AUXL) Stock Chart for Saturday, April, 21, 2018